[email protected]

国际临床研究杂志

International Journal of Clinical Research

您当前位置:首页 > 精选文章

International Journal of Clinical Research. 2026; 10: (8) ; 10.12208/j.ijcr.20260388 .

A case of generalized pustular psoriasis induced by targeted immune combined therapy in primary hepatocellular carcinoma with literature review
原发性肝癌靶免联合治疗诱发泛发性脓疱型银屑病1例并文献复习

作者: 邱海玲 *

贺州市广济医院 广西贺州

*通讯作者: 邱海玲,单位:贺州市广济医院 广西贺州; ;

引用本文: 邱海玲 原发性肝癌靶免联合治疗诱发泛发性脓疱型银屑病1例并文献复习[J]. 国际临床研究杂志, 2026; 10: (8) : 76-78.
Published: 2026/8/8 14:16:41

摘要

我国原发性肝癌发病率居高不下,靶向联合免疫治疗已成为中晚期患者的重要手段,皮肤毒性是其较常见不良反应。银屑病为多因素介导的慢性炎症性皮肤病,在抗肿瘤药物作用下易急性加重。本文报告1例47岁男性中国肝癌分期(CNLC)Ⅱb期肝癌患者,合并慢性乙肝、肝硬化及十余年寻常型银屑病,经导管动脉化疗栓塞术+肝动脉灌注化疗(TACE+HAIC)联合多纳非尼、替雷利珠单抗治疗后,稳定期银屑病迅速进展为泛发性脓疱型银屑病。结合病史、影像、检验及专科会诊确诊为靶免治疗诱发泛发性脓疱型银屑病。经停药、抗炎、护肝及皮肤综合处理后症状改善。文章结合病例与文献,分析其临床特点、发病机制、鉴别要点及分级处理方案。

关键词: 原发性肝癌;靶向免疫治疗;多纳非尼;替雷利珠单抗;泛发性脓疱型银屑病;免疫相关不良反应

Abstract

The incidence rate of primary liver cancer in China remains persistently high. Targeted combined immunotherapy has become a crucial treatment for patients in the intermediate and advanced stages, with cutaneous toxicity being a relatively common adverse reaction. Psoriasis is a chronic inflammatory skin disease mediated by multiple factors and is prone to acute exacerbation under the influence of antitumor drugs. This report presents a case of a 47-year-old male patient with stage IIb liver cancer (China Liver Cancer Staging (CNLC) classification), who also had chronic hepatitis B, cirrhosis, and psoriasis vulgaris lasting over a decade. After treatment with Transcatheter Arterial Chemoembolization +Hepatic Arterial Infusion Chemotherapy (TACE+HAIC) combined with donafenib and toripalimab, his stable-phase psoriasis rapidly progressed to generalized pustular psoriasis. Based on medical history, imaging, laboratory tests, and specialist consultations, the diagnosis of generalized pustular psoriasis induced by targeted-immunotherapy was confirmed. Symptoms improved following drug discontinuation, anti-inflammatory therapy, liver protection, and comprehensive skin management. The article analyzes the clinical features, pathogenesis, key differentials, and graded treatment strategies by combining this case with relevant literature.

Key words: Primary liver cancer; Targeted immunotherapy; Donafenib; Toripalimab; Generalized pustular psoriasis; Immune-related adverse reactions

参考文献 References

[1] 高梦婷,焦曦,董凤晓,等. 免疫检查点抑制剂致严重免疫相关皮肤不良反应的临床特点和诊疗策略研究[J]. 肿瘤综合治疗电子杂志,2023,9(4):66-77.

[2] 肖嵘,刘佳倪. 系统性硬皮病靶向治疗研究进展[J]. 皮肤性病诊疗学杂志,2024,31(5):287-296.

[3] 张国兴,邹勤光,贾春祎. 免疫检查点抑制剂斯鲁利单抗诱发红皮病型银屑病1例并文献复习[J]. 肿瘤研究与临床,2025,37(1):67-69. 

[4] 洪毅勇,朱琳,黄影,等. 免疫检查点抑制剂引起的药疹及其应对策略[J]. 皮肤性病诊疗学杂志,2021,28(6):513-519. 

[5] 施国明,黄晓勇,任正刚,等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志,2021,20(12):1241-1258. 

[6] 李洁,汪荣华,谢晓蕾. 替雷利珠单抗致银屑病样皮疹1例[J]. 药物流行病学杂志,2024,33(10):1189-1195. 

[7] 宫学宇,李怀朋,刘帅,等. 肝硬化或肝癌伴银屑病患者肝移植术后免疫抑制剂的治疗经验[J]. 中国临床实用医学,2024,15(6):13-15. 

[8] 中华医学会皮肤性病学分会,中国医师协会皮肤科医师分会,中国老年医学学会皮肤医学分会. 免疫检查点抑制剂相关皮肤不良反应诊治中国专家共识(2024版)[J]. 中华医学杂志,2024,104(20):1790-1803.